In vitro and ex vivo models of multiple sclerosis

Drug Discovery Today

Volumn 21, Issue 9, 2016, Pages 1504-1511

  Madill, Martin ^a   Fitzgerald, Denise ^b   O'Connell, Kara E ^c   Dev, Kumlesh K ^c   Shen, Sanbing ^a   FitzGerald, Una ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; BRAIN; CELL CULTURE; HUMAN; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PRECLINICAL STUDY; PROCEDURES; TISSUE CULTURE TECHNIQUE;

ANIMALS; BRAIN; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; TISSUE CULTURE TECHNIQUES;

EID: 84988410239     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.05.018     Document Type: Review

References (54)

1. 1 Louis, J.C., et al. Autocrine inhibition of mitotic activity in cultured oligodendrocyte-type-2 astrocyte (O-2A) precursor cells. Glia 6 (1992), 30–38.
2. 2 Dugas, J.C., Emery, B., Purification and culture of oligodendrocyte lineage cells. Cold Spring Harb. Protoc. 2013 (2013), 810–814.
3. 3 Horiuchi, M., et al. Differing in vitro survival dependency of mouse and rat NG2+ oligodendroglial progenitor cells. J. Neurosci. Res. 88 (2010), 957–970.
4. 4 Bechler, M.E., et al. CNS myelin sheath lengths are an intrinsic property of oligodendrocytes. Curr. Biol. 25 (2015), 2411–2416.
5. 5 Barnett, S.C., Crouch, D.H., The effect of oncogenes on the growth and differentiation of oligodendrocyte type 2 astrocyte progenitor cells. Cell Growth Differ. 6 (1995), 69–80.
6. 6 Buntinx, M., et al. Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury: morphology and oligodendrocyte-specific gene expression. J. Neurocytol. 32 (2003), 25–38.
7. 7 De Vries, G.H., Boullerne, A.I., Glial cell lines: an overview. Neurochem. Res. 35 (2010), 1978–2000.
8. 8 Barateiro, A., Fernandes, A., Temporal oligodendrocyte lineage progression: in vitro models of proliferation, differentiation and myelination. Biochim. Biophys. Acta 1843 (2014), 1917–1929.
9. 9 Chew, L.J., et al. Finding degrees of separation: experimental approaches for astroglial and oligodendroglial cell isolation and genetic targeting. J. Neurosci. Methods 236 (2014), 125–147.
10. 10 Zhu, B., et al. Isolation and long-term expansion of functional, myelinating oligodendrocyte progenitor cells from neonatal rat brain. Curr. Protoc. Stem Cell Biol., 31, 2014 2D.17.1-15.
11. 11 Dincman, T.A., et al. Isolation of cortical mouse oligodendrocyte precursor cells. J. Neurosci. Methods 209 (2012), 219–226.
12. 12 Hu, B.Y., et al. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat. Protoc. 4 (2009), 1614–1622.
13. 13 Douvaras, P., et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Rep. 3 (2014), 250–259.
14. 14 Chen, H., et al. Human umbilical cord Wharton's jelly-derived oligodendrocyte precursor-like cells for axon and myelin sheath regeneration. Neural Regen. Res. 8 (2013), 890–899.
15. 15 Leite, C., et al. Differentiation of human umbilical cord matrix mesenchymal stem cells into neural-like progenitor cells and maturation into an oligodendroglial-like lineage. PLoS ONE, 9, 2014, e111059.
16. 16 Song, B., et al. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res. 8 (2012), 259–273.
17. 17 Mikkelsen, T.S., et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 454 (2008), 49–55.
18. 18 Di Ruscio, A., et al. Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death Dis., 6, 2015, e1806.
19. 19 Muller, D., et al. Time course of synaptic development in hippocampal organotypic cultures. Brain Res. Dev. Brain Res. 71 (1993), 93–100.
20. 20 Stoppini, L., et al. Lesion-induced neurite sprouting and synapse formation in hippocampal organotypic cultures. Neuroscience 57 (1993), 985–994.
21. 21 Gogolla, N., et al. Preparation of organotypic hippocampal slice cultures for long-term live imaging. Nat. Protoc. 1 (2006), 1165–1171.
22. 22 Harrer, M.D., et al. Live imaging of remyelination after antibody-mediated demyelination in an ex-vivo model for immune mediated CNS damage. Exp. Neurol. 216 (2009), 431–438.
23. 23 Birgbauer, E., et al. Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. J. Neurosci. Res. 78 (2004), 157–166.
24. 24 Pritchard, A.J., et al. Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures. PLoS ONE, 9, 2014, e99444.
25. 25 Levi, G.M.H., Nouvelles recherches sur le tissu nerveux cultivé in vitro. Morphologie, croissance et relations réciproques des neurones. Arch. Biol. 52 (1941), 133–278.
26. 26 Zhang, H., et al. Central nervous system remyelination in culture – a tool for multiple sclerosis research. Exp. Neurol. 230 (2011), 138–148.
27. 27 Vallstedt, A., et al. Multiple dorsoventral origins of oligodendrocyte generation in the spinal cord and hindbrain. Neuron 45 (2005), 55–67.
28. 28 Miron, V.E., et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 16 (2013), 1211–1218.
29. 29 Sobottka, B., et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am. J. Pathol. 175 (2009), 1160–1166.
30. 30 Sim, F.J., et al. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J. Neurosci. 22 (2002), 2451–2459.
31. 31 Ling, C., et al. In situ activation of antigen-specific CD8+ T cells in the presence of antigen in organotypic brain slices. J. Immunol. 180 (2008), 8393–8399.
32. 32 Crawford, A.H., et al. Oligodendrocyte progenitors: adult stem cells of the central nervous system?. Exp. Neurol. 260 (2014), 50–55.
33. 33 Natrajan, M.S., et al. Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain 138 (2015), 3581–3597.
34. 34 O'Sullivan, C., Dev, K.K., Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling. J. Cell. Sci. 128 (2015), 3878–3887.
35. 35 Coelho, R.P., et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323 (2007), 626–635.
36. 36 Jung, C.G., et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55 (2007), 1656–1667.
37. 37 Miron, V.E., et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 63 (2008), 61–71.
38. 38 Mattes, H., et al. Design and synthesis of selective and potent orally active S1P5 agonists. ChemMedChem 5 (2010), 1693–1696.
39. 39 O'Sullivan, C., et al. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J. Neuroinflammation, 13, 2016, 31.
40. 40 Sheridan, G.K., Dev, K.K., S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia 60 (2012), 382–392.
41. 41 Miron, V.E., et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 176 (2010), 2682–2694.
42. 42 Mei, F., et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat. Med. 20 (2014), 954–960.
43. 43 Najm, F.J., et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature 522 (2015), 216–220.
44. 44 Colello, R.J., Sato-Bigbee, C., Purification of oligodendrocytes and their progenitors using immunomagnetic separation and Percoll gradient centrifugation. Curr. Protoc. Neurosci., 2001 Chapter 3, Unit 3.12.
45. 45 Niu, J., et al. An efficient and economical culture approach for the enrichment of purified oligodendrocyte progenitor cells. J. Neurosci. Methods 209 (2012), 241–249.
46. 46 McCarthy, K.D., de Vellis, J., Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85 (1980), 890–902.
47. 47 Vitry, S., et al. Mouse oligospheres: from pre-progenitors to functional oligodendrocytes. J. Neurosci. Res. 58 (1999), 735–751.
48. 48 Lu, Y., et al. Isolation and culture of human oligodendrocyte precursor cells from neurospheres. Brain Res. Bull. 118 (2015), 17–24.
49. 49 Douvaras, P., Fossati, V., Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat. Protoc. 10 (2015), 1143–1154.
50. 50 Stacpoole, S.R., et al. High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology. Stem Cell Rep. 1 (2013), 437–450.
51. 51 Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12 (2013), 252–264.
52. 52 Rowitch, D.H., Kriegstein, A.R., Developmental genetics of vertebrate glial-cell specification. Nature 468:7321 (2010), 214–222.
53. 53 Kucenas, S., Adventures in Wonderland. PLoS Genetics, 11(4), 2015.
54. 54 Najm, F.J., et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nat Biotechnol. 31:5 (2013), 426–433.